<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103332</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-AGT01-003</org_study_id>
    <secondary_id>2021-003776-13</secondary_id>
    <nct_id>NCT05103332</nct_id>
  </id_info>
  <brief_title>Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)</brief_title>
  <acronym>KARDIA-2</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic&#xD;
      blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran&#xD;
      as add-on therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 26, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24-Hour Mean Systolic Blood Pressure (SBP) from Baseline to Month 3, Assessed by Ambulatory Blood Pressure Monitoring (ABPM)</measure>
    <time_frame>Baseline to Month 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Office SBP from Baseline to Month 3</measure>
    <time_frame>Baseline to Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-Hour Mean SBP from Baseline to Month 6, Assessed by ABPM</measure>
    <time_frame>Baseline to Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office SBP from Baseline to Month 6</measure>
    <time_frame>Baseline to Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-Hour Mean Diastolic Blood Pressure (DBP) from Baseline to Months 3 and 6, Assessed by ABPM</measure>
    <time_frame>Baseline to Months 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office DBP from Baseline to Months 3 and 6</measure>
    <time_frame>Baseline to Months 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Daytime and Nighttime Mean SBP and DBP from Baseline to Month 3 and Month 6, assessed by ABPM</measure>
    <time_frame>Baseline to Months 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Angiotensinogen (AGT) from Baseline through Month 6</measure>
    <time_frame>Baseline through Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Zilebesiran (Add-on to Olmesartan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a run-in on olmesartan, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Add-on to Olmesartan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a run-in on olmesartan, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to olmesartan. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zilebesiran (Add-on to Amlodipine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a run-in on amlodipine, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Add-on to Amlodipine)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Following a run-in on amlodipine, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to amlodipine. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zilebesiran (Add-on to Indapamide)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Following a run-in on indapamide, eligible participants will receive zilebesiran on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Add-on to Indapamide)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Following a run-in on indapamide, eligible participants will receive placebo on Day 1 of a 6-month double-blind treatment period as add-on to indapamide. Thereafter, participants will receive zilebesiran once every 6 months during the open-label extension period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <description>Olmesartan administered orally</description>
    <arm_group_label>Placebo (Add-on to Olmesartan)</arm_group_label>
    <arm_group_label>Zilebesiran (Add-on to Olmesartan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine administered orally</description>
    <arm_group_label>Placebo (Add-on to Amlodipine)</arm_group_label>
    <arm_group_label>Zilebesiran (Add-on to Amlodipine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indapamide</intervention_name>
    <description>Indapamide administered orally</description>
    <arm_group_label>Placebo (Add-on to Indapamide)</arm_group_label>
    <arm_group_label>Zilebesiran (Add-on to Indapamide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered by SC injection</description>
    <arm_group_label>Placebo (Add-on to Amlodipine)</arm_group_label>
    <arm_group_label>Placebo (Add-on to Indapamide)</arm_group_label>
    <arm_group_label>Placebo (Add-on to Olmesartan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zilebesiran</intervention_name>
    <description>Zilebesiran administered by SC injection</description>
    <arm_group_label>Placebo (Add-on to Amlodipine)</arm_group_label>
    <arm_group_label>Placebo (Add-on to Indapamide)</arm_group_label>
    <arm_group_label>Placebo (Add-on to Olmesartan)</arm_group_label>
    <arm_group_label>Zilebesiran (Add-on to Amlodipine)</arm_group_label>
    <arm_group_label>Zilebesiran (Add-on to Indapamide)</arm_group_label>
    <arm_group_label>Zilebesiran (Add-on to Olmesartan)</arm_group_label>
    <other_name>ALN-AGT01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Office SBP at Screening as follows:&#xD;
&#xD;
               1. ≥155 mmHg and ≤180 mmHg for patients with untreated hypertension&#xD;
&#xD;
               2. ≥145 mmHg and ≤180 mmHg for patients on antihypertensive medications&#xD;
&#xD;
          -  24-hour mean SBP &gt;130 mmHg and ≤160 mmHg by ABPM after at least 4 weeks of run-in on&#xD;
             protocol-specified background antihypertensive medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary or orthostatic hypertension&#xD;
&#xD;
          -  Elevated potasium &gt;5 mEq/L&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73m^2&#xD;
&#xD;
          -  Received an investigational agent within the last 30 days&#xD;
&#xD;
          -  Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed&#xD;
             Type 2 diabetes mellitus&#xD;
&#xD;
          -  History of any cardiovascular event within 6 months prior to randomization&#xD;
&#xD;
          -  History of intolerance to SC injection(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alnylam Clinical Trial Information Line</last_name>
    <phone>1-877-ALNYLAM</phone>
    <email>clinicaltrials@alnylam.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alnylam Clinical Trial Information Line</last_name>
    <phone>1-877-256-9526</phone>
    <email>clinicaltrials@alnylam.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High blood pressure</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Hypertensive</keyword>
  <keyword>siRNA</keyword>
  <keyword>Angiotensinogen</keyword>
  <keyword>AGT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

